MORRISVILLE, North Carolina, January 9, 2012 /PRNewswire/ --

nContact, Inc., the leading innovator in epicardial ablation devices, today announced its technology will be presented by physicians in two posters at the 17th Annual International Boston Atrial Fibrillation Symposium, January 12-14 in Boston, Massachusetts.  nContact will be showcasing its Numeris® Coagulation System with VisiTrax® and next generation EPi-Sense™ Coagulation System at its Boston AF Symposium booth #301.

nContact's epicardial ablation device integrates suction, perfusion and radiofrequency energy to ensure consistent cardiac tissue contact and create visible, continuous lesions on the epicardium of a beating heart. Access to the posterior of the atrium is achieved with unique access through the diaphragm with a SUBTLE (sub-thoracic, total endoscopic) approach for minimally invasive, closed-chest epicardial ablation.  

The technology will be presented in the following posters on Friday, January 13, 2012 available from 7:30 am until 6:30 pm:

• Poster # 10 titled: "Prospective Reveal® XT Outcomes for the Convergent Atrial Fibrillation Ablation Procedure"
  Evaluates long-term outcomes of a multidisciplinary ablation procedure to treat persistent or longstanding persistent AF, as monitored by Reveal XT technology (Medtronic); presented by Borut Gersak, MD, of University Medical Center Ljubljana, Ljubljiana, Slovenia.
• Poster #20 titled: "Multicenter Retrospective Outcomes for the Treatment of Atrial Fibrillation Using the Multidisciplinary Convergent Procedure"
  Examines outcomes of closed chest AF ablation procedure on patients with persistent or longstanding persistent AF across four U.S. sites; presented by Dr. Keith Golden of St. Vincent Hospital, Indianapolis, IN.

About nContact, Inc.

nContact is a medical device company founded in 2005 with a mission to develop devices for the endoscopic treatment of arrhythmias, including atrial fibrillation (AF). The Numeris® Coagulation System with VisiTrax® is based on the unique integration of suction, perfusion, and RF energy to ensure the creation of visible, non-conductive, continuous, bi-atrial lesions on the epicardium of a beating heart.

To date, the Numeris® Coagulation System with VisiTrax® is indicated for endoscopic coagulation of cardiac tissue in the United States. nContact has initiated IDE clinical studies for the treatment of AF in both open and closed chest procedures.

The Numeris™ and EPi-Sense™ Coagulation Systems with VisiTrax® have CE Mark approval in Europe for the coagulation of cardiac tissue for the treatment of atrial fibrillation and atrial flutter. For more information, please visit http://www.ncontactinc.com.  

    Media Contacts
    Beth Rose                Kimberly Muscara
    nContact, Inc            The Ruth Group
    T +1-919-655-1566        T +1-646-536-7011
    brose@ncontactinc.com    kmuscara@theruthgroup.com

SOURCE nContact, Inc.